PORPHYSOMES-A PARADIGM SHIFT IN TARGETED DRUG DELIVERY
A novel drug delivery system is the one that ensures optimum dose at the right time, at the right location. Porphysomes are among those drug delivery systems. Porphysomes are a means of vesicular drug delivery systems. They are liposome-like structures composed completely of porphyrin lipid. The porphysomes encapsulates the active medicament in vesicular structure. They are having an aqueous core which can be loaded with the medicament. They have the capacity to destroy the disease tissues. They absorb the heat in the near infrared region and release this heat to destroy the diseased tissues. Porphysomes are having immense applications in the field of positron-electron therapy (PET), photoacoustic imaging, photothermal therapy etc. This review article discusses regarding the Porphysome-the drug delivery system, its advantages and disadvantages, composition, method of preparation, applications and various aspects related to the porphysomal drug delivery.
2. Vijaya SB, Mrudula T, Pavankumar V. Imperitive note on novel drug delivery system. J Nanomed Nanotechnol 2011;2:125.
3. Kumar V, Sharma A, Sharma A, Joshi G, Dhillon V. Recent advances in ndds(novel drug delivery system) for delivery of antihypertensive drugs. Int J Drug Dev Res 2011;3:252-9.
4. Gaurav T, Ruchi T, Birendra S, Bhati L, Pandey S, Pandey P, et al. Drug delivery systems: an updated review. Int J Pharm Invest 2012;2:2-11.
5. Bhargav E, Madhuri N, Ramesh K, Anand M, Ravi V. Targeted drug delivery-a review. World J Pharm Pharm Sci 2013;3:150-69.
6. Reddy PD, Swarnalatha D. Recent advances in novel drug delivery systems. Int J Pharm Res 2010;2:2025-27.
7. Charman WN, Chan HK, Finnin BC, Charman SA. Drug delivery: a key factor in realising the full therapeutic potential of drugs. Drug Dev Res 1999;46:316-27.
8. Manivannan R, Kugalur GP. Recent advances in novel drug delivery systems. Int J Res Ayurveda Pharm 2010;1:316-26.
9. Nuno M, Christiane D, Catarina PR. Recent advances in drug delivery systems. J Biomater Nanobiotechnol 2011;2:510-26.
10. Bassam ARH. Overview on drug delivery system. Pharma Anal Acta 2012;3:137.
11. Aswathy SN, Vidya KM, Saranya TR, Sreeja CN. Emulsomes: a novel liposomal formulation for sustained drug delivery. Int Res J Pharm Appl Sci 2013;3:192-6.
12. Elizabeth H, Gang Z. Porphysome nanotechnology: a paradigm shift in lipid-based supramolecular structures. Nano Today 2014;9:212-22.
13. Mastrobattista E, Koning GA, Storm G. Immunoliposomes for targeted delivery antitumour drugs. Adv Drug Delivery Rev 1999;40:103-27.
14. Shefrin S, Sreelaxmi CS, Vishnu V, Sreeja CN. Enzymosomes: a rising effectual tool for targeted drug delivery system. Int J Appl Pharm 2017;9:1-9.
15. Archana P, Satyendra M, Alka T, Krishna M. Targeted drug delivery (site-specific drug delivery). J Sci Ind Res 2004; 63:230-47.
16. Kenneth KN, Misa T, Cheng CS, Gang Z. Self-sensing porphysomes for fluorescence-guided photothermal therapy. Bioconjug Chem 2015;26:345-51.
17. Vijey A, Samuel GG. Structure-affinity relationship and characterization of benzoporphyrins as potent inhibitors of YAP oncoprotein in silico experiments. Int J Pharm Pharm Sci 2015;7:278-84.
18. Shah H, Patel J. Bicelle: a lipid nanostructure for transdermal delivery. J Crit Rev 2016;3:17-22.
19. Soumya S, Doney AB, Sabitha M. Current trends in lipid-based delivery systems and its applications in drug delivery. Asian J Pharm Clin Res 2012;4:4-9.
20. Upendra B, Sindhu D, Nagavendra K, Wahid K. Liposomal formulations in clinical use: an updated review. Pharmaceutics 2017;9:12.
21. Gert F, Torsten K, Armin W, Alfred B. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res 2010;27:1469-86.
22. Jing L, Xuling W, Ting Z, Chunling W, Zhenjun H, Xiang L, Yihui D. A review on phospholipids and their main applications in drug delivery systems. Am J Plant Sci 2015;10:81-98.
23. Jindal K. Niosomes as a potential carrier system: a review. Int J Pharm Chem Biol Sci 2015;5:947-59.
24. Ravi B, Sreekanth N, Bhargavi S, Babu RC. Vesicular drug delivery system-an overview. Res J Pharm Biol Chem Sci 2014;4:462-74.
25. Sunil K. Vesicular drug delivery systems: a novel approach for drug targeting. Int J Drug Delivery 2013;5:121-30.
26. Cheng SJ, Marta O, Liyang C, Brian CW. Nanoparticle-enabled selective destruction of the prostate tumor using MRI-guided focal photothermal therapy. Prostate 2016;76:1169-89.
27. Lili Z, Hong W, Bin H, Lijuan Z. Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics. Theratonics 2016;6:762-74.
28. Jilong W, Jingjing Q. A review of organic nanomaterials in photothermal cancer therapy. Cancer Res Front 2016;2:67-84.
29. Patrizia A, Kristian B, Keith AC, Thomas HF. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011;61:250-81.
30. Xianghong Z, Tang L, Zhihong L, Xiangsheng Z. Progress of photodynamic therapy applications in the treatment of musculoskeletal sarcoma (review). Oncol Lett 2014;8:1403-8.
31. Agostinis P, berg K, Cengel KA, Foster TH. Photodynamic therapy of cancer: an update. CA Cancer J Cin 2011;61:250-81.
32. Januz B, Joanna P, Joanna Z. Nanoparticles of titanium and zinc oxides as a novel agent in tumor treatment: a review. Nanoscale Res Lett 2017;12:1-15.
33. Judith W, Paul CB, Sarah EB. Contrast agents for molecular photoacoustic imaging. Nat Methods 2016;13:639-50.
34. Minghua X, Lihong V. Photoacoustic imaging in biomedicine. Rev Sci Instrum 2006;77:4110.
35. Langstrom T, Kihlberg Bergstrom. Structure of 2-Benzoylamino-5-diethylamino-1,6,6alambda4-triselena-3,4-diazapentalene. Acta Chem Scandinavia 1999;53:651.
36. Saraswathi M, Umasankar K, Jayachandra RP. A review on liposomes. Int J Res Pharm Nanol Sci 2014;3:159-69.
37. Rutuja RD, Snehal VG, Megha KB, Priyanka AA. A review on liposomes. World J Pharm Pharm Sci 2016;5:506-17.
38. Bhama SK, Rakhi K, Lakshmi P, Deepa TV, Sreeja CN. Formulation and evaluation of niosomal suspension of cefixime. Asian J Pharm Clin Res 2017;10:194-201.
39. Gnaneswaran S, Kuberan D, Vinodhini VM, Swamy RSV, Ebenezer WW, Kumar JS. Fasting plasma glucose and glycolated haemoglobin in prediction of diabetic retinopathyin rural population. Int J Pharm Clin Res 2014;6:40-5.
40. Alan NS. Hemoglobin research and the origins of molecular medicines. Blood 2008;112:3927-38.
41. Stefan H, Bernhard K. Chlorophyll breakdown in higher plants. Biochim Biophys Acta 2011;1807:977-88.
42. Aris H, Su L, Ronald H, Michael KD. Chlorophyll extract from microalgae: a review on the process engineering aspects 2010:1-10. http://dx.doi.org/10.1155/2010/391632
43. Galina PB, Ekaterina AS. Myoglobin and mitochondria: how does the oxygen storeâ€ work? J Phys Chem Biophys 2013;3:1-7.
44. George AO, Daniel JG. Myoglobin: an essential hemoprotein in striated muscle. J Exp Biol 2004;207:3441-6.
45. Shane BK, Pradeep PA. Regualation of gene expression. J Exp Biol 2010;213:2741-7.
46. Caroline PB, Henrik JA. Myoglobin-induced lipid oxidation-a review. J Agric Food Chem 2002;50:3887-97.
47. Nelson DL, Cox M. Lehninger, principles of biochemistry. 3rd ed. Worth Publishing: New York; 2000.
48. Samuel IB. Biosynthesis of phycobilins. Chem Rev 1993; 93:785-802.
49. Rosella S, Federica B, Agostino P, Isabella C. Current therapeutic strategies for advanced pancreatic cancer: a review for clinicians. World J Clin Oncol 2016;7:27-43.
50. Mac Laughlin CM, Ding L, Jin C, Cao P, Siddiqui I, Hwang DM, et al. Porphysome nanoparticles for enhanced photothermal therapy in a patient-derived orthotopic pancreas xenograft cancer model: a pilot study. J Biomed Opt 2016;21:84002.
51. Bozeman CB, Carver BS, Caldito G, Venable DD. Prostate cancer in patient with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/ml. Urology 2005;66:803-73.
52. Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA 2017;317:2532-42.
53. Jin CS, Overchuk M, Cui L, Wilson BC, Bristow RG, Chen J, et al. Nanoparticle-enabled selective destruction of the prostate tumor using MRI-guided focal photothermal therapy. Prostate 2016;76:1169-81.
54. Maya S, Sabitha M, Shanthikumar VN, Jayakumar R. Phytomedicine-loaded polymeric nanomedicines: potential cancer therapeutics. Adv Polym Sci 2013;254:203-39.
55. Iacono P, Battaglia PM, Falcomata B, Bandello F. Central serous chorioretinopathy treatments: a mini review. Ophthalmic Res 2016;55:76-83.
56. Alenjandra D, Alexandre M, Ali D, Elodie B. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retinal Eye Res 2015;48:82-118.
57. Marwan AA. Advances in the treatment of central serous retinopathy. Saudi J Ophthalmol 2015;29:278-86.
58. Alexandros GS. Nanotechnology-enabled thernostics of lung cancer. Cancer Res 2016;76:5870-80.
59. Kelly ML, Timothy FM. Lung cancer: diagnosis, treatment, principles and screening. Am Fam Physician 2015;91:250-6.
60. Roy SH, John VH, Scott ML. Lung cancer. N Eng J Med 2008;359:1367-80.
61. Marilena VI, Rosa V, Gianpiero DL, Valentina d. Micro RNA signatures in human ovarian cancer. Cancer Res 2007; 67:8699-707.